Total Payments
$1,784
2023 Payments
$28.50
Companies
22
Transactions
70
Medicare Patients
1,753
Medicare Billing
$212,684
Payment Breakdown by Category
Food & Beverage$1,784 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,784 | 70 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Galderma Laboratories, L.P. | $365.09 | 22 | $0 (2021) |
| Ortho Dermatologics, a division of Bausch Health US, LLC | $219.56 | 7 | $0 (2021) |
| Merz North America, Inc. | $211.26 | 3 | $0 (2019) |
| Allergan Inc. | $176.30 | 5 | $0 (2017) |
| Encore Dermatology Inc. | $165.87 | 5 | $0 (2017) |
| Regeneron Healthcare Solutions, Inc. | $125.00 | 1 | $0 (2022) |
| Valeant Pharmaceuticals North America LLC | $113.22 | 5 | $0 (2017) |
| VYNE Pharmaceuticals Inc. | $53.32 | 2 | $0 (2020) |
| PFIZER INC. | $53.25 | 3 | $0 (2021) |
| LEO Pharma Inc. | $36.12 | 2 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $28.50 | 1 | Amgen Inc. ($28.50) |
| 2022 | $163.01 | 3 | Regeneron Healthcare Solutions, Inc. ($125.00) |
| 2021 | $71.91 | 4 | Galderma Laboratories, L.P. ($21.14) |
| 2020 | $91.86 | 4 | VYNE Pharmaceuticals Inc. ($53.32) |
| 2019 | $267.79 | 7 | Merz North America, Inc. ($167.38) |
| 2018 | $331.65 | 13 | Ortho Dermatologics, a division of Bausch Health US, LLC ($161.56) |
| 2017 | $829.63 | 38 | Galderma Laboratories, L.P. ($254.47) |
All Payment Transactions
70 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/04/2023 | Amgen Inc. | Enbrel (Biological), Otezla | Food and Beverage | In-kind items and services | $28.50 | General |
| Category: Inflammation | ||||||
| 12/15/2022 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/07/2022 | Sebela Pharmaceuticals Inc. | PRAMOSONE (Drug), NAFTIN | Food and Beverage | In-kind items and services | $22.67 | General |
| Category: DERMATOLOGY - TOPICAL CORTICOSTEROIDANSTHETIC | ||||||
| 12/03/2022 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $15.34 | General |
| Category: Dermatology | ||||||
| 12/13/2021 | Ortho Dermatologics, a division of Bausch Health US, LLC | ARAZLO (Drug), ALTRENO, ONEXTON | Food and Beverage | In-kind items and services | $20.64 | General |
| Category: Dermatology | ||||||
| 12/10/2021 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $11.66 | General |
| Category: Dermatology | ||||||
| 08/30/2021 | PFIZER INC. | EUCRISA (Drug) | Food and Beverage | In-kind items and services | $18.47 | General |
| Category: DERMATOLOGY | ||||||
| 02/09/2021 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $21.14 | General |
| 12/16/2020 | VYNE Pharmaceuticals Inc. | AMZEEQ (Drug) | Food and Beverage | In-kind items and services | $26.33 | General |
| Category: Treatment of ACNE Vulgaris | ||||||
| 11/23/2020 | Galderma Laboratories, L.P. | — | Food and Beverage | In-kind items and services | $20.69 | General |
| 10/20/2020 | VYNE Pharmaceuticals Inc. | AMZEEQ (Drug) | Food and Beverage | In-kind items and services | $26.99 | General |
| Category: Treatment of ACNE Vulgaris | ||||||
| 09/03/2020 | Sun Pharmaceutical Industries Inc. | ABSORICA LD (Drug) | Food and Beverage | Cash or cash equivalent | $17.85 | General |
| Category: Dermatology | ||||||
| 12/19/2019 | Ortho Dermatologics, a division of Bausch Health US, LLC | ALTRENO (Drug), DUOBRII | Food and Beverage | In-kind items and services | $21.80 | General |
| Category: DERMATOLOGY | ||||||
| 12/12/2019 | PFIZER INC. | EUCRISA (Drug) | Food and Beverage | In-kind items and services | $16.49 | General |
| Category: DERMATOLOGY | ||||||
| 12/10/2019 | Merz North America, Inc. | XEOMIN (Biological) | Food and Beverage | Cash or cash equivalent | $167.38 | General |
| Category: DERMATOLOGY | ||||||
| 11/07/2019 | PFIZER INC. | EUCRISA (Drug) | Food and Beverage | In-kind items and services | $18.29 | General |
| Category: DERMATOLOGY | ||||||
| 08/27/2019 | DERMIRA, INC. | — | Food and Beverage | In-kind items and services | $12.50 | General |
| 07/11/2019 | Mayne Pharma Inc. | DORYX (Drug) | Food and Beverage | In-kind items and services | $15.77 | General |
| Category: DERMATOLOGY | ||||||
| 02/27/2019 | Ortho Dermatologics, a division of Bausch Health US, LLC | ALTRENO (Drug), RETIN-A MICRO, ONEXTON | Food and Beverage | In-kind items and services | $15.56 | General |
| Category: DERMATOLOGY | ||||||
| 12/21/2018 | Ortho Dermatologics, a division of Bausch Health US, LLC | SILIQ (Drug) | Food and Beverage | In-kind items and services | $144.55 | General |
| Category: DERMATOLOGY | ||||||
| 10/16/2018 | Galderma Laboratories, L.P. | EPIDUO FORTE (Drug) | Food and Beverage | In-kind items and services | $18.65 | General |
| Category: ACNE | ||||||
| 09/14/2018 | Mission Pharmacal Company | — | Food and Beverage | In-kind items and services | $16.53 | General |
| 08/22/2018 | Exeltis, USA Inc. | Neosalus (Drug) | Food and Beverage | In-kind items and services | $22.63 | General |
| 04/25/2018 | Merz North America, Inc. | XEOMIN | Food and Beverage | Cash or cash equivalent | $29.39 | General |
| 04/17/2018 | Galderma Laboratories, L.P. | EPIDUO FORTE (Drug) | Food and Beverage | In-kind items and services | $18.06 | General |
| Category: ACNE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 476 | 647 | $86,291 | $62,201 |
| 2022 | 9 | 497 | 662 | $81,763 | $59,266 |
| 2021 | 9 | 425 | 581 | $76,672 | $57,618 |
| 2020 | 11 | 355 | 474 | $47,755 | $33,598 |
Total Patients
1,753
Total Services
2,364
Medicare Billing
$212,684
Procedure Codes
39
All Medicare Procedures & Services
39 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 149 | 192 | $37,550 | $26,713 | 71.1% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 122 | 172 | $19,816 | $14,301 | 72.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 28 | 28 | $6,749 | $4,588 | 68.0% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 47 | 86 | $4,893 | $3,836 | 78.4% |
| J7308 | Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | Office | 2023 | 12 | 12 | $4,689 | $3,497 | 74.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 24 | 31 | $4,334 | $3,353 | 77.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 32 | 40 | $3,967 | $2,983 | 75.2% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 37 | 44 | $3,319 | $2,165 | 65.2% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 12 | 12 | $750.48 | $588.36 | 78.4% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 13 | 30 | $223.92 | $175.56 | 78.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 155 | 184 | $37,058 | $25,681 | 69.3% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 125 | 172 | $20,530 | $15,300 | 74.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 34 | 43 | $6,119 | $4,832 | 79.0% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2022 | 60 | 91 | $5,404 | $4,266 | 78.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 16 | 16 | $3,969 | $3,027 | 76.3% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 42 | 47 | $3,652 | $2,449 | 67.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 30 | 32 | $3,252 | $2,408 | 74.0% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 20 | 21 | $1,346 | $962.09 | 71.5% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 15 | 56 | $431.76 | $340.43 | 78.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 138 | 180 | $35,340 | $26,171 | 74.1% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2021 | 106 | 146 | $17,377 | $13,208 | 76.0% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 30 | 30 | $7,329 | $5,648 | 77.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 35 | 49 | $4,928 | $3,842 | 78.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 25 | 30 | $4,188 | $3,254 | 77.7% |
| 11103 | Tangential biopsy of additional skin lesion | Office | 2021 | 35 | 61 | $3,724 | $2,979 | 80.0% |
About Dr. Lenora Felderman, MD
Dr. Lenora Felderman, MD is a Dermatology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/22/2007. The National Provider Identifier (NPI) number assigned to this provider is 1235264011.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Lenora Felderman, MD has received a total of $1,784 in payments from pharmaceutical and medical device companies, with $28.50 received in 2023. These payments were reported across 70 transactions from 22 companies. The most common payment nature is "Food and Beverage" ($1,784).
As a Medicare-enrolled provider, Felderman has provided services to 1,753 Medicare beneficiaries, totaling 2,364 services with total Medicare billing of $212,684. Data is available for 4 years (2020–2023), covering 39 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Location New York, NY
- Active Since 02/22/2007
- Last Updated 12/18/2024
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1235264011
Products in Payments
- EPIDUO FORTE (Drug) $248.29
- XEOMIN (Biological) $181.87
- Hylatopic (Drug) $165.87
- ACZONE (Drug) $152.20
- SILIQ (Drug) $144.55
- DUPIXENT (Biological) $125.00
- AMZEEQ (Drug) $53.32
- EUCRISA (Drug) $53.25
- ALTRENO (Drug) $37.36
- ENSTILAR (Drug) $36.12
- VALCHLOR MECHLORETHAMINE (Drug) $35.84
- Ameluz (Drug) $34.46
- ONEXTON (Drug) $33.21
- Enbrel (Biological) $28.50
- OPZELURA (Drug) $27.00
- PRAMOSONE (Drug) $22.67
- Neosalus (Drug) $22.63
- ARAZLO (Drug) $20.64
- Finacea (Drug) $20.62
- ABSORICA LD (Drug) $17.85
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in New York
David Cohen, M.d, M.D
Dermatology — Payments: $3.1M
Dermatology $3.1M
Dr. Amy Wechsler, M.d, M.D
Dermatology — Payments: $2.8M
Dermatology $2.8M
Dr. Alexandra Golant, M.d, M.D
Dermatology — Payments: $2.7M
Dermatology $2.7M
Emma Guttman, Md, MD
Dermatology — Payments: $2.2M
Dermatology $2.2M
Dr. Joshua Zeichner, Md, MD
Dermatology — Payments: $2.1M
Dermatology $2.1M
Dr. Mark Lebwohl
Dermatology — Payments: $2.0M
Dermatology $2.0M